TerminatedNot Applicable

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

Stopped: Study terminated by PI

United States50 participantsStarted 2021-03-22

Plain-language summary

This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not. The purpose of this research is to gather information on the effectiveness of the EndoPAT device, which is FDA-approved to assess the health of a patient's blood vessels. These assessments will help doctors leading the study determine the reasons why patients may develop shortness of breath (dyspnea) when being treated with carfilzomib and ways to better prevent this shortness of breath.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 * Confirmed diagnosis of multiple myeloma * Newly-diagnosed multiple myeloma, or relapsed/refractory multiple myeloma with receipt of 1-3 previous lines of therapy and with a 2-week washout from prior therapy * Receiving carfilzomib as either standard-of-care therapy or as part of a clinical trial Exclusion Criteria: * Previous receipt of anthracycline chemotherapy * Previous receipt of carfilzomib * Four or more previous lines of therapy * Active pregnancy at the time of enrollment

What they're measuring

Endothelial Function and Dyspnea Associations in Multiple Myeloma Patients

Timeframe: 2 months

Trial details

NCT IDNCT04827563

SponsorUniversity of Chicago

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-08

View on ClinicalTrials.gov More Multiple Myeloma trials